CA
NZ
UK
AU
IND
US
…
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -157.04M | -125.75M | -59.46M | -17.32M | -8.96M |
| Net income | -152.84M | -125.80M | -58.07M | -17.32M | -8.96M |
| Selling general administrative | 47.93M | 35.08M | 24.87M | 5.70M | 3.97M |
| Reconciled depreciation | 0.00M | 0.00M | 0.00M | - | 0.00M |
| Ebit | -161.25M | -125.70M | -60.84M | -8.90M | -6.21M |
| Ebitda | -156.44M | -124.46M | -60.82M | -8.89M | -6.21M |
| Depreciation and amortization | 4.81M | 1.25M | 0.02M | 0.00M | 0.00M |
| Non operating income net other | 1.55M | - | - | - | - |
| Operating income | -161.25M | -125.70M | -60.84M | -12.73M | -6.92M |
| Other operating expenses | 161.25M | 125.70M | 60.84M | 12.73M | 6.92M |
| Interest expense | 4.21M | 0.05M | 1.40M | - | 1.34M |
| Interest income | 2.66M | 1.20M | - | - | - |
| Net interest income | 2.66M | 1.20M | 1.40M | - | -0.76M |
| Income tax expense | -4.21M | 0.05M | -1.39M | -3.83M | 0.63M |
| Total revenue | 0.00M | 0.00M | 0.00M | - | 0.00M |
| Total operating expenses | 161.25M | 125.70M | 60.84M | 12.73M | 6.92M |
| Total other income expense net | 4.21M | -0.05M | 1.38M | -3.83M | -0.71M |
| Net income from continuing ops | -157.04M | -125.75M | -59.46M | - | -17.32M |
| Net income applicable to common shares | -157.04M | -125.75M | -59.46M | -15.01M | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 97.55M | 152.91M | 223.33M | 118.19M | 10.22M |
| Other current assets | 1.19M | -0.00M | 0.00M | -0.00M | -0.00M |
| Total liab | 12.19M | 12.47M | 15.06M | 12.60M | 2.61M |
| Total stockholder equity | 85.36M | 140.44M | 208.26M | 105.58M | 7.61M |
| Other current liab | 8.69M | 7.21M | 3.87M | 4.26M | -0.00M |
| Common stock | 0.03M | 0.03M | 0.03M | 0.02M | 0.04M |
| Capital stock | 0.03M | 0.03M | 0.03M | 0.02M | - |
| Retained earnings | -560.90M | -462.11M | -305.07M | -179.32M | -111.66M |
| Other assets | - | 0.03M | 0.03M | 0.11M | 0.19M |
| Cash | 4.09M | 5.40M | 44.44M | 2.50M | 9.22M |
| Total current liabilities | 12.19M | 12.47M | 15.06M | 12.60M | 2.61M |
| Current deferred revenue | - | - | - | - | 1.32M |
| Net debt | -4.09M | -5.40M | -44.44M | -2.50M | -8.85M |
| Short term debt | - | - | - | - | 0.36M |
| Short long term debt total | - | - | - | - | 0.36M |
| Other stockholder equity | 646.23M | 602.52M | 513.30M | 284.88M | 119.24M |
| Property plant equipment | - | - | - | 0.00M | 0.01M |
| Total current assets | 97.51M | 152.87M | 223.30M | 118.07M | 9.98M |
| Net tangible assets | - | 140.44M | 208.26M | 105.58M | 115.68M |
| Short term investments | 92.23M | 142.93M | 167.47M | 114.60M | 80.16M |
| Net receivables | - | 0.51M | 0.09M | 0.08M | 0.25M |
| Inventory | - | 4.04M | 11.30M | 0.90M | 0.52M |
| Accounts payable | 3.51M | 5.26M | 11.19M | 8.35M | 0.92M |
| Accumulated other comprehensive income | - | - | - | - | -0.01M |
| Common stock total equity | - | 0.03M | - | 0.02M | 0.01M |
| Retained earnings total equity | - | -462.11M | - | - | - |
| Non currrent assets other | 0.04M | 0.03M | 0.03M | 0.11M | 0.23M |
| Non current assets total | 0.04M | 0.03M | 0.03M | 0.11M | 0.24M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 19.73M | -54.12M | -34.45M | -80.16M | -80.16M |
| Change to liabilities | 3.76M | 2.85M | 7.82M | 0.16M | 1.34M |
| Total cashflows from investing activities | 19.73M | -54.12M | -34.45M | -80.16M | -160.33M |
| Net borrowings | -0.05M | - | -0.11M | -0.37M | -0.29M |
| Total cash from financing activities | 45.02M | 187.94M | 28.47M | 17.48M | 6.54M |
| Change to operating activities | 10.68M | -10.71M | 3.03M | -0.03M | 1.52M |
| Net income | -157.04M | -125.75M | -59.46M | -17.32M | -8.96M |
| Change in cash | -39.05M | 41.95M | -33.78M | 6.98M | 0.53M |
| Begin period cash flow | 44.44M | 2.50M | 36.28M | 2.24M | 1.71M |
| End period cash flow | 5.40M | 44.44M | 2.50M | 9.22M | 2.24M |
| Total cash from operating activities | -103.80M | -91.87M | -27.81M | -10.50M | -6.00M |
| Issuance of capital stock | 43.43M | 185.31M | 20.53M | - | 17.76M |
| Depreciation | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Other cashflows from investing activities | - | - | - | -80.16M | - |
| Change to account receivables | -0.51M | -0.51M | 0.07M | -0.51M | -0.17M |
| Sale purchase of stock | 42.73M | - | - | 113.89M | 17.76M |
| Other cashflows from financing activities | 1.67M | 2.63M | 8.06M | -0.25M | 6.54M |
| Change to netincome | 38.43M | 41.74M | 20.79M | 2.77M | 5.04M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.01M |
| Change receivables | -0.43M | - | - | - | -0.10M |
| Cash flows other operating | 11.48M | - | - | - | -0.12M |
| Cash and cash equivalents changes | -39.05M | - | - | - | 6.98M |
| Change in working capital | 7.45M | -7.86M | 10.85M | 1.51M | 0.70M |
| Stock based compensation | 44.19M | 40.49M | 20.78M | 1.21M | 0.52M |
| Other non cash items | 1.59M | 1.25M | 0.02M | 0.27M | 1.03M |
| Free cash flow | -103.80M | -91.87M | -27.81M | -10.50M | -6.01M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics Inc |
0.13 3.45% |
3.90 | - | - | - | 1.65 | -0.43 |
| NVO Novo Nordisk A/S |
0.01 0.02% |
40.31 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
4.59 0.85% |
547.09 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
1.45 0.16% |
904.35 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134
786 629 1376
20
| Name | Title | Year Born |
|---|---|---|
| Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD | CEO & Director | 1960 |
| Mr. Maged S. Shenouda M.B.A., MBA, R.Ph, R.Ph. | Chief Financial Officer | 1964 |
| Mr. Charles S. Ence CPA, M.B.A. | Chief Accounting & Compliance Officer | 1965 |
| Dr. Paolo Manfredi M.D., Ph.D. | Chief Scientific Officer | 1962 |
| Ms. Gina DiGuglielmo | VP & Head of Clinical Operations | NA |
| Dr. Marco Pappagallo M.D. | Chief Medical Officer | 1958 |
| Mr. John Hixon | Head of Commercial | NA |
| Dr. Richard M. Mangano | Consultant | 1950 |
| Dr. Sergio Traversa M.B.A., Pharm.D. | CEO & Director | 1960 |
| Mr. Maged S. Shenouda M.B.A., R.Ph. | Chief Financial Officer | 1964 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...